N -(正丁基)脱氧半乳糖霉素
|
|
|
- CAS号:
- 141206-42-0
- 英文名:
- N-Butyl-1-deoxygalactonojirimycin
- 英文别名:
- OGT-923);ACT-434964;Lucerastat;N-Butyl-1-deoxygalactonojirimycin;Migalastat Impurity 1 (Lucerastat);Lucerastat
(N-Butyldeoxygalactonojirimycin;(2R,3S,4R,5S)-1-Butyl-2-(hydroxyMethyl)-3,4,5-piperidinetriol;3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3S,4R,5S)-;(2R,3S,4R,5S)-1-(But-1-yl)-2-(hydroxymethyl)piperidine-3,4,5-triol;N-(But-1-yl)deoxygalactonojirimycin, (2R,3S,4R,5S)-1-(But-1-yl)-2-(hydroxymethyl)-3,4,5-trihydroxypiperidine
- 中文名:
- N -(正丁基)脱氧半乳糖霉素
- 中文别名:
- 米加司他杂质1;化合物 T32923;N -(正丁基)脱氧半乳糖霉素
- CBNumber:
- CB21232075
- 分子式:
- C10H21NO4
- 分子量:
- 219.28
- MOL File:
- 141206-42-0.mol
|
|
|
N -(正丁基)脱氧半乳糖霉素化学性质
-
熔点:
-
123-124°C
-
|
-
沸点:
-
394.7±42.0 °C(Predicted)
-
|
-
密度:
-
1.234±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Hygroscopic, -20°C Freezer, Under Inert Atmosphere
-
|
-
溶解度:
-
DMF: 20 mg/mL; DMSO: 30 mg/mL; Ethanol: 5 mg/mL; PBS (pH 7.2): 10 mg/mL
-
|
-
形态:
-
A crystalline solid
-
|
-
酸度系数(pKa):
-
13.72±0.70(Predicted)
-
|
-
稳定性:
-
Hygroscopic
-
|
N -(正丁基)脱氧半乳糖霉素性质、用途与生产工艺
Lucerasta 是Miglustat 的半乳糖形式，是具有口服活性的葡萄糖酰神经酰胺合成酶 (GCS) 的抑制剂。Lucerastat 有用于Fabry 疾病研究的潜能。
Fabry patient-derived fibroblasts with the genotypes R301G (residual -GalA activity; 20%) R220X (<3%) and W162X (<1%).
Cell Viability Assay.
|
Cell Line:
|
Fabry patient-derived fibroblasts with the genotypes R301G (residual -GalA activity; 20%) R220X (<3%) and W162X (<1%).
|
|
Concentration:
|
|
|
Incubation Time:
|
9 days.
|
|
Result:
|
Dose-dependently inhibited GCS, reducing glucosylceramide and increasing sphingomyelin.
|
Lucerastat (1200 mg/kg/day food admix), a GCS inhibitor, reduces Gb3 in the absence of residual -GalA activity.
|
Animal Model:
|
Fabry mice (Gla
-/0
and Gla
-/-
, n = 5 or 6 for each gender).
|
|
Dosage:
|
1200 mg/kg/day food admix.
|
|
Administration:
|
Food admix for 20 weeks.
|
|
Result:
|
Reduced lipid storage in two major organs affected by FD: mean Gb3 in the kidneys (-33%, p<0.01). and α-galactose- terminated glycosphingolipids in the dorsal root ganglia (-48%, p<0.05). In the liver of the Fabry mice, mean glucosylceramide (GlcCer (24:0)) was reduced (-59%, p<0.001) in addition to Gb3 (24:1) (-37%, p<0.05) demonstrating substrate reduction through GCS inhibition.
|
N -(正丁基)脱氧半乳糖霉素
上下游产品信息
上游原料
下游产品
141206-42-0, N -(正丁基)脱氧半乳糖霉素 相关搜索:
- Inhibitors
- Glycosidase Inhibitors
- 米加司他杂质1
- 化合物 T32923
- N -(正丁基)脱氧半乳糖霉素
- 141206-42-0
- Migalastat Impurity 1 (Lucerastat)
- 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3S,4R,5S)-
- OGT-923)
- Lucerastat
(N-Butyldeoxygalactonojirimycin
- ACT-434964
- Lucerastat
- (2R,3S,4R,5S)-1-Butyl-2-(hydroxyMethyl)-3,4,5-piperidinetriol
- N-(But-1-yl)deoxygalactonojirimycin, (2R,3S,4R,5S)-1-(But-1-yl)-2-(hydroxymethyl)-3,4,5-trihydroxypiperidine
- (2R,3S,4R,5S)-1-(But-1-yl)-2-(hydroxymethyl)piperidine-3,4,5-triol
- N-Butyl-1-deoxygalactonojirimycin